Skip to contentG
Ginkgo Bioworks Holdings, Inc.
G
DNAGinkgo Bioworks Holdings, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$98.29M$98.29Mderived−33.8% vs Q4 2021 No earnings release is on file for this quarter. Its figures came with the 10-K.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR
+48.0% vs Q3 2022
Net Income-$175.47M-$175.47MderivedN/M vs Q4 2021N/M vs Q3 2022 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$230,864,000N/M Operating Cash Flowderived-$104,531,000N/M Free Cash Flowderived-$130,176,000N/M Margins · derivedOperating margin-234.9%+899.7 pt vs Q4 2021
Net margin-178.5%+899.4 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 13, 2023 · 72 d after period end